What is Bioxodes?
Bioxodes SA is a clinical-stage biopharmaceutical firm dedicated to pioneering novel treatments for thrombotic and inflammatory conditions. Its primary asset, BIOX-101, is a first-in-class drug candidate designed for stroke intervention. The drug's distinct dual mechanism of action underpins an innovative pipeline aimed at both treating and preventing thromboinflammatory diseases. Bioxodes has established a robust intellectual property portfolio, holding both granted and pending patents globally for BIOX-101, underscoring its commitment to innovation in a critical therapeutic area.
How much funding has Bioxodes raised?
Bioxodes has raised a total of $23.9M across 2 funding rounds:
Seed
$3.5M
Series A
$20.4M
Seed (2013): $3.5M, investors not publicly disclosed
Series A (2025): $20.4M led by Newton Biocapital
Key Investors in Bioxodes
Newton Biocapital
Newton Biocapital is a venture capital firm specializing in life sciences, focusing on maturing innovation and supporting the growth of portfolio companies. They leverage strong ties to European and Japanese life science ecosystems to identify promising investment opportunities, particularly in chronic health conditions.
What's next for Bioxodes?
With the recent major strategic investment, Bioxodes is poised for significant expansion and advancement of its pipeline. The substantial capital infusion, totaling $23.9M, is anticipated to fuel critical clinical trials for BIOX-101 and potentially broaden its therapeutic applications. This funding round, characterized as enterprise-level, suggests a strategic focus on scaling operations, advancing regulatory pathways, and preparing for potential commercialization. The company's trajectory indicates a move towards later-stage development and market entry, leveraging its innovative drug candidate to address unmet needs in stroke and other thromboinflammatory diseases.
See full Bioxodes company page
